<DOC>
	<DOCNO>NCT02338479</DOCNO>
	<brief_summary>This prospective non-therapeutic study , assess long-term toxicity pediatric HCT hematologic malignancy . This study collaboration Pediatric Blood Marrow Transplant Consortium ( PBMTC ) , Center International Blood Marrow Transplant Research ( CIBMTR ) , National Marrow Transplant Program ( NMDP ) Resource Clinical Investigation Blood Marrow Transplantation ( RCI-BMT ) CIBMTR . The study enroll pediatric patient undergo myeloablative HCT hematologic malignancy PBMTC site .</brief_summary>
	<brief_title>Natural History Biology Long-Term Late Effects Following Hematopoietic Cell Transplant Childhood Hematologic Malignancies</brief_title>
	<detailed_description>This prospective non-therapeutic study , assess long-term toxicity pediatric HCT hematologic malignancy . This study collaboration Pediatric Blood Marrow Transplant Consortium ( PBMTC ) , Center International Blood Marrow Transplant Research ( CIBMTR ) , National Marrow Transplant Program ( NMDP ) Resource Clinical Investigation Blood Marrow Transplantation ( RCI-BMT ) CIBMTR . The study enroll pediatric patient undergo myeloablative HCT hematologic malignancy PBMTC site . The study examine hypothesis survivor pediatric HCT risk late organ toxicity identifiable biomarkers present within first two year follow HCT predictive late adverse outcome allow early identification patient risk .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Age le 22 year admission HCT 2 . Planned allogeneic HCT donor stem cell source . There studyspecific criterion HLAmatching 3 . Disease disease status criterion 1 . Acute lymphoblastic leukemia/lymphoma complete morphologic remission define M1 marrow ( &lt; 5 % blast ) evidence active extramedullary disease within 30 day start condition regimen ; OR 2 . Myelodysplasia ( regardless subtype ) less 10 % marrow blast within 30 day start condition regimen ; OR 3 . Acute myelogenous leukemia complete morphologic remission define M1 marrow ( &lt; 5 % blast ) evidence extramedullary disease within 30 day start condition regimen ; OR 4 . Juvenile myelomonocytic leukemia ; OR 5 . Chronic myelogenous leukemia exclude refractory blast crisis . 4 . Planned myeloablative conditioning regimen , define regimen include one follow backbone agent : 1 . Busulfan ≥ 12.8 mg/kg total dose ( IV PO ) . PKbased dosing allow , intent total overall dose ≥ 12.8 mg/kg ; OR 2 . Total Body Irradiation ≥ 1200 cGy fractionate ; OR 3 . Treosulfan ≥ 30 g/m2 total dose IV 5 . Enrollment follow NMDP research protocol : 1 . Protocol Research Database Hematopoietic Cell Transplantation , Other Cellular Therapies Marrow Toxicity Injuries 2 . Protocol Research Sample Repository Allogeneic Hematopoietic Stem Cell Transplantation Marrow Toxic Injuries 6 . Written inform consent document sign patient age great equal 18 year patient developmentally able provide consent . The informed consent document sign parent legal guardian patient 's age le 18 year patient old 18 year , developmentally unable provide consent . Assent obtain accord guideline patient 's transplant institution . 1 . Prior allogeneic autologous HCT 2 . Patients renal disease prior start HCT conditioning require use dialysis time enrollment and/or GFR &lt; 60 mL/min/1.73 m2 3 . Patients osteopenia osteoporosis treat bisphosphonate medication time prior enrollment 4 . Patients preexist diabetes hyperglycemia treat insulin oral hypoglycemic medication time enrollment 5 . Patients uncontrolled viral , bacterial , fungal protozoal infection time study enrollment 6 . Karnofsky performance score Lansky PlayPerformance Scale Score &lt; 60 time study enrollment 7 . Known inherited constitutional predisposition cancer include , limit Down Syndrome , LiFraumeni syndrome , Fanconi Anemia , patient BRCA1 BRCA2 mutation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>